These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 16253504)

  • 1. Dydrogesterone in the reduction of recurrent spontaneous abortion.
    El-Zibdeh MY
    J Steroid Biochem Mol Biol; 2005 Dec; 97(5):431-4. PubMed ID: 16253504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dydrogesterone support in threatened miscarriage.
    El-Zibdeh MY; Yousef LT
    Maturitas; 2009 Dec; 65 Suppl 1():S43-6. PubMed ID: 20007011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study.
    Ghosh S; Chattopadhyay R; Goswami S; Chaudhury K; Chakravarty B; Ganesh A
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1871-6. PubMed ID: 25056464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dydrogesterone in threatened miscarriage: a Malaysian experience.
    Pandian RU
    Maturitas; 2009 Dec; 65 Suppl 1():S47-50. PubMed ID: 20005647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dydrogesterone in threatened abortion: pregnancy outcome.
    Omar MH; Mashita MK; Lim PS; Jamil MA
    J Steroid Biochem Mol Biol; 2005 Dec; 97(5):421-5. PubMed ID: 16293412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for threatened miscarriage.
    Qureshi NS
    Maturitas; 2009 Dec; 65 Suppl 1():S35-41. PubMed ID: 19945236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial.
    Walch K; Hefler L; Nagele F
    J Matern Fetal Neonatal Med; 2005 Oct; 18(4):265-9. PubMed ID: 16318978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hormonal treatment of recurrent spontaneous abortions].
    Karag'ozova Zh; Chernev T; Atanasova D; Pavlova E; Dimitrova V; Khranov Iu; Vragaleva S
    Akush Ginekol (Sofiia); 2007; 46(3):3-7. PubMed ID: 18018774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of human chorionic gonadotropin in recurrent abortion.
    Sandler SW; Baillie P
    S Afr Med J; 1979 May; 55(21):832-5. PubMed ID: 472911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study.
    Chakravarty BN; Shirazee HH; Dam P; Goswami SK; Chatterjee R; Ghosh S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(5):416-20. PubMed ID: 16213136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical uses of progestational agents in the endocrine department of Chelsea Hospital for Women.
    Osmond-Clarke F
    Bull Schweiz Akad Med Wiss; 1970 Oct; 25(4-6):522-5. PubMed ID: 5534330
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of dydrogesterone in recurrent (habitual) abortion.
    Gruber CJ; Huber JC
    J Steroid Biochem Mol Biol; 2005 Dec; 97(5):426-30. PubMed ID: 16188436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion.
    MacDonald RR; Goulden R; Oakey RE
    Obstet Gynecol; 1972 Sep; 40(3):394-402. PubMed ID: 4560047
    [No Abstract]   [Full Text] [Related]  

  • 14. Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders: an outlook.
    Schindler AE
    Horm Mol Biol Clin Investig; 2016 Aug; 27(2):49-53. PubMed ID: 27662647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dydrogesterone (Duphaston) in the prevention of risk of ultrasound guided amniocentesis].
    Korczyński J
    Ginekol Pol; 2000 Aug; 71(8):709-13. PubMed ID: 11082907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dydrogesterone has no effect on uterine fibroids when used to prevent miscarriage in pregnant women with uterine fibroids.
    Wang S; Wang XT; Liu RH; Liu M; Wu YR; Huang XY; Zhao N; Mu YL
    Ginekol Pol; 2017; 88(12):679-685. PubMed ID: 29303226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trial.
    Qureshi NS; Edi-Osagie EC; Ogbo V; Ray S; Hopkins RE
    BJOG; 2005 Nov; 112(11):1536-41. PubMed ID: 16225575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical observation on effect of Chinese herbal medicine plus human chorionic gonadotropin and progesterone in treating anticardiolipin antibody-positive early recurrent spontaneous abortion].
    Shu J; Miao P; Wang RJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2002 Jun; 22(6):414-6. PubMed ID: 12585182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dydrogesterone and the immunology of pregnancy.
    Raghupathy R; Szekeres-Bartho J
    Horm Mol Biol Clin Investig; 2016 Aug; 27(2):63-71. PubMed ID: 26812877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteal phase support in ovarian induction cycles using human chorionic gonadotropin or oral progestagens.
    Zayed FF; El-Jallad MF; Al-Chalabi HA
    Saudi Med J; 2003 Jan; 24(1):34-6. PubMed ID: 12590270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.